Education
About Us
Working with TipRanks
Follow Us
Ocugen Inc (OCGN)
:OCGN
OCGN Stock Chart & Stats
$1.43
-$0.04(-4.99%)
At close: 4:00 PM EST
$1.43
-$0.04(-4.99%)
Day’s Range― - ―
52-Week Range$0.52 - $1.90
Previous CloseN/A
Volume1.89M
Average Volume (3M)5.85M
Market Cap
$446.60M
Enterprise ValueN/A
Total Cash (Recent Filing)$32.56M
Total Debt (Recent Filing)$32.96M
Price to Earnings (P/E)―
Beta1.36
Next Earnings
Mar 27, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding312,304,750
10 Day Avg. Volume2,987,049
30 Day Avg. Volume5,853,609
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)7.36
Price to Sales (P/S)53.80
P/FCF Ratio-4.79
Enterprise Value/Market Cap0.00
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$9.00Price Target Upside529.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial PerformanceOcugen reported higher-than-expected revenues of $1.8M, compared to consensus estimates of $0.6M, reflecting better financial performance.
Gene Therapy AdvancementsOcugen's gene therapy programs are making significant progress, with the pivotal Stargardt disease study enrolling quicker than expected.
Strategic PartnershipsOcugen's license agreement with Kwangdong Pharmaceutical indicates industry interest in their OCU400 product, highlighting potential for future revenue.
Bears Say
Financial LossesOcugen reported 3Q25 results with a net loss of ($20.1M), wider than the ($14.7M) in 2Q25, which is due to ramping up of the GARDian study and enrolling the liMeliGhT study in retinitis pigmentosa (RP).
Operational ChallengesThe previously planned merger agreement, effectively a spinout transaction for Ocugen, with Ocugen's Orthcellix subsidiary was terminated due to failure to secure the required funding.
Resource Allocation IssuesOcugen is unlikely to advance the NeoCart program on its own, as it would require resources that could otherwise be used to advance its high-value ophthalmology gene therapy programs.
Ocugen News
OCGN FAQ
What was Ocugen Inc’s price range in the past 12 months?
Ocugen Inc lowest stock price was $0.52 and its highest was $1.90 in the past 12 months.
What is Ocugen Inc’s market cap?
Ocugen Inc’s market cap is $446.60M.
When is Ocugen Inc’s upcoming earnings report date?
Ocugen Inc’s upcoming earnings report date is Mar 27, 2026 which is in 126 days.
How were Ocugen Inc’s earnings last quarter?
Ocugen Inc released its earnings results on Nov 05, 2025. The company reported -$0.07 earnings per share for the quarter, missing the consensus estimate of -$0.056 by -$0.014.
Is Ocugen Inc overvalued?
According to Wall Street analysts Ocugen Inc’s price is currently Undervalued.
Does Ocugen Inc pay dividends?
Ocugen Inc does not currently pay dividends.
What is Ocugen Inc’s EPS estimate?
Ocugen Inc’s EPS estimate is -0.06.
How many shares outstanding does Ocugen Inc have?
Ocugen Inc has 312,304,750 shares outstanding.
What happened to Ocugen Inc’s price movement after its last earnings report?
Ocugen Inc reported an EPS of -$0.07 in its last earnings report, missing expectations of -$0.056. Following the earnings report the stock price went down -1.399%.
Which hedge fund is a major shareholder of Ocugen Inc?
Currently, no hedge funds are holding shares in OCGN
Ocugen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.00 (529.37% Upside)
$9.00 (529.37% Upside)
Blogger Sentiment
Bullish
OCGN Sentiment 70%
Sector Average 69%
Sector Average 69%
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.7%
Last 30 Days ▲ 0.9%
Last 30 Days ▲ 0.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
48.42%
12-Months-Change
Fundamentals
Return on Equity
-289.93%
Trailing 12-Months
Asset Growth
32.19%
Trailing 12-Months
Company Description
Ocugen Inc
Ocugen, Inc. is a biotechnology company focused on developing innovative therapies to treat and prevent eye diseases. Primarily operating in the biopharmaceutical sector, Ocugen's core products include its lead candidate, OCU300, an innovative gene therapy for retinal diseases, and a partnership with Bharat Biotech to develop and commercialize COVAXIN, a COVID-19 vaccine, for the U.S. market. The company aims to leverage its expertise in gene therapies and vaccines to address unmet medical needs in ophthalmology and infectious diseases.
OCGN Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant advancements in gene therapy programs and strategic partnerships, alongside promising clinical data. However, the company faced increased operating expenses and a decline in cash position. Overall, the positive advancements and strategic positioning contribute to an optimistic outlook.View all OCGN earnings summariesOCGN Stock 12 Month Forecast
Average Price Target
$9.00
▲(529.37% Upside)
Technical Analysis
Ownership Overview
1.68% Insiders
5.77% Mutual Funds
0.22% Other Institutional Investors
88.09% Public Companies and Individual Investors